An improved quantitative method for evaluating neurological deficits in mice with focal cerebral ischemia

Acta Physiologica Sinica

Volumn 55, Issue 6, 2003, Pages 742-747

  Wei, Er Qing ^a   Zhu, Chao Yang ^a   Xu, Qiu Qin ^a   Yu, Yue Ping ^a   Zhu, Ye Fei ^a   Zheng, Min Zhi ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Focal cerebral ischemia; Hemiparesis; Mouse; Neurobiology; Neurological examination; pranlukast, 4 oxo 8 p (4 phenylbutyloxy) benzoylamino 2 (tetrazol 5 yl) 4H 1 benzopyran hemihydrate (ONO 1078)

Indexed keywords

NEUROPROTECTIVE AGENT; PRANLUKAST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN CORTEX; BRAIN ISCHEMIA; CELL DENSITY; CONTROLLED STUDY; CORRELATION COEFFICIENT; HEMIPARESIS; HIPPOCAMPUS; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROLOGICAL COMPLICATION; NEUROPROTECTION; NONHUMAN;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; BRAIN ISCHEMIA; CHROMONES; FEMALE; HIPPOCAMPUS; INFARCTION, MIDDLE CEREBRAL ARTERY; LEUKOTRIENE ANTAGONISTS; MALE; MICE; MICE, INBRED ICR; NEUROLOGIC EXAMINATION; NEUROPROTECTIVE AGENTS;

EID: 0346333302     PISSN: 03710874     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986;17:472-476.
2. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989;20:84-91.
3. Tatlisumak T, Takano K, Carano RA, Miller LP, Foster AC, Fisher M. Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. Stroke 1998;29:1952-1958.
4. Yonemori F, Yamaguchi T, Yamada H, Tamura A. Evaluation of a motor deficit after chronic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1998;18:1099-1106.
5. Petullo D, Masonic K, Lincoln C, Wibberley L, Teliska M, Yao DL. Model development and behavioral assessment of focal cerebral ischemia in rats. Life Sciences 1999;64:1099-1108.
6. de Courten Myers GM, Kleinholz M, Wagner KR, Myers RE. Stroke assessment: morphometric infarct size versus neurologic deficit. J Neurosci Methods 1998;83:151-157.
7. Sarraf-Yazdi S, Sheng H, Brinkhous AD, Pearlstein RD, Warner DS. Effects of postischemic halothane administration on outcome from transient focal cerebral ischemia in the rat. J Neurosurg Anesthesiol 1999;11:31-36.
8. Yonemori F, Yamaguchi T, Nakayama H, Narita K, Hojo S, Tamura A. Effect of JTP-2942, a novel thyrotropin-releasing hormone analog, on motor deficits after chronic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2000;20:74-81.
9. Hattori K, Lee H, Hurn PD, Crain BJ, Traystman RJ, DeVries AC. Cognitive deficits after focal cerebral ischemia in mice. Stroke 2000;31:1939-1944.
10. Hunter AJ, Hatcher J, Virley D, Nelson P, Irving E, Hadingham SJ, Parsons AA. Functional assessments in mice and rats after focal stroke. Neuropharmacol 2000;39:806-816.
11. DeVries AC, Nelson RJ, Traystman RJ, Hurn PD. Cognitive and behavioral assessment in experimental stroke research: will it prove useful? Neurosci Biobehav Rev 2001;25:325-342.
12. Cenci MA, Whishaw IQ, Schaller T, Animal models of neurological deficits: how relavant is the rat? Nature Rew Neurosci 2002;3:574-579.
13. Zeng LH, Zhang WP, Wang RD, Wang PL, Wei EQ. Protective effect of ONO-1078, aleukotriene antagonist, on focal cerebral ischemia in mice. Acta Pharmac Sin 2001;36:148-150 (Chinese, English abstract).
14. Zhang WP, Wei EQ, Mei RH, Zhu CY, Zhao MH. Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia in rats. Acta Pharmacol Sin 2002;23:871-877.
15. Mao Y, Yang GY, Zhou LF, Stern JD, Betz AL. Focal cerebral ischemia in the mouse: description of a model and effects of permanent and temporary occlusion. Brain Res Mol Brain Res 1999, 63:366-370.
16. Zhu LJ, Zhang WP, Wei EQ, Luo JH. Alteration in expressional levels of NMDA receptor subunit proteinξ1 ε1 and ε2 in brain regions after permanent ischemia in mice. J Zhejiang Univ Med Sci 2002;31:68-71 (Chinese, English abstract).
17. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752-2758.
18. Eliasson MJ, Sampei K, Mandir AS, Hurn PD, Traystman RJ, Bao J, et al. Poly (ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med 1997;3:1089-1095.